Daniella Beckman net worth and biography

Daniella Beckman Biography and Net Worth

CFO of Tango Therapeutics

Daniella Beckman brings over 20 years of strategic, financial and operational experience to her role at Tango overseeing finance, investor relations and business development. Most recently, she has provided financial consulting for Tango since its inception, and prior to that, for another early-stage biotechnology company, Neon Therapeutics. Previously, Daniella was the Chief Financial Officer of Idenix Pharmaceuticals, where she oversaw finance, investor relations and IT until it was acquired by Merck in 2014. Prior to serving as Chief Financial Officer, Daniella served as corporate controller for Idenix. She previously held finance positions at Coley Pharmaceuticals, Biogen Idec and PricewaterhouseCoopers. Daniella serves on the boards of directors of Vor Biopharma, and Blueprint Medicines.

Daniella has a Bachelor of Science degree in business administration/accounting from Boston University.

What is Daniella Beckman's net worth?: The estimated net worth of Daniella Beckman is at least $1.53 million as of February 4th, 2025. Beckman owns 154,232 shares of Tango Therapeutics stock worth more than $1,526,897 as of December 5th. This net worth approximation does not reflect any other assets that Beckman may own. Learn More about Daniella Beckman's net worth.
How do I contact Daniella Beckman?: The corporate mailing address for Beckman and other Tango Therapeutics executives is 12860 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. Tango Therapeutics can also be reached via phone at 857-320-4900 and via email at [email protected]. Learn More on Daniella Beckman's contact information.
Has Daniella Beckman been buying or selling shares of Tango Therapeutics?: Daniella Beckman has not been actively trading shares of Tango Therapeutics within the last three months. Most recently, Daniella Beckman sold 4,284 shares of the business's stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $2.99, for a transaction totalling $12,809.16. Following the completion of the sale, the chief financial officer now directly owns 154,232 shares of the company's stock, valued at $461,153.68. Learn More on Daniella Beckman's trading history.
Who are Tango Therapeutics' active insiders?: Tango Therapeutics' insider roster includes Douglas Barry (Chief Legal Officer), Daniella Beckman (CFO), Adam Crystal (President, Research & Development), Mace Rothenberg (Director), and Barbara Weber (CEO). Learn More on Tango Therapeutics' active insiders.
Are insiders buying or selling shares of Tango Therapeutics?: During the last year, insiders at the sold shares 11 times. They sold a total of 3,496,769 shares worth more than $26,422,881.47. The most recent insider tranaction occured on October, 23rd when Major Shareholder Rock Ventures Iv L.P. Third sold 477,401 shares worth more than $4,845,620.15. Insiders at Tango Therapeutics own 7.5% of the company. Learn More about insider trades at Tango Therapeutics.
Information on this page was last updated on 10/23/2025.

Daniella Beckman Insider Trading History at Tango Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/4/2025	Sell	4,284	$2.99	$12,809.16	154,232
2/6/2024	Sell	1,908	$12.56	$23,964.48	134,214

Daniella Beckman Buying and Selling Activity at Tango Therapeutics

Tango Therapeutics Company Overview

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $9.90

$9.46

$10.22

50 Day Range

MA: $8.54

$6.91

$10.92

2 Week Range

Now: $9.90

$1.03

$11.20

Volume

2,780,322 shs

Average Volume

2,935,051 shs

Market Capitalization

$1.33 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.72